Niagen Bioscience, Inc.
NAGE · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Mar 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $129M | $99.6M | +29.9% |
| Operating income | $16.3M | $7.73M | +111% |
| Net income | $17.4M | $8.55M | +103% |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 4, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $27.2M | $34.0M | −20.0% |
| Operating income | −$1.60M | $4.20M | |
| Net income | −$1.20M | $4.60M |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was Niagen Bioscience's revenue in FY2025?
- $129M in FY2025 (Fiscal year ended Dec 31, 2025), +29.9% vs $99.6M a year earlier, per its 10-K filed Mar 2026.
- Was Niagen Bioscience profitable in FY2025?
- Yes: net income was $17.4M and operating income $16.3M in FY2025.
- What was Niagen Bioscience's revenue in Q3 2026?
- $27.2M (−20.0% vs a year earlier), per its Form 10-Q filed Nov 4, 2026.